ProCE Banner Activity

Managing Bipolar Depression and Mixed Presentations

Slideset Download
This presentation on managing bipolar depression and mixed presentations reviews the dimensional continuum of mood disorder presentations from unipolar to bipolar disorder, evidence supporting the use and limitations of mood-stabilizing drugs and second-generation antipsychotics for the treatment of unipolar and bipolar depression, limitations of monoaminergic antidepressants in bipolar depression and major depression with mixed features, and evidence-based patient treatment plans based upon patient and disease state-specific characteristics.

Released: May 09, 2022

Expiration: May 08, 2023

No longer available for credit.

Share

Faculty

Charles DeBattista

Charles DeBattista, DMH, MD

Chief, Depression Research Clinic
Director, Medical Student Education in Psychiatry
Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, California

Roger McIntyre

Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
University of Toronto, Canada
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Toronto, Canada
Board Chair, Depression and Bipolar Support Alliance
Board of Directors
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This program is supported by educational grants from:

AbbVie Inc.

Intra Cellular Therapies

Faculty Disclosure

Primary Author

Charles DeBattista, DMH, MD

Chief, Depression Research Clinic
Director, Medical Student Education in Psychiatry
Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, California

Charles DeBattista, DMH, MD, has disclosed that he has received consultant/advisor/speaker fees from AbbVie and Corcept; and funds for research support from Biolite, Compass, Janssen, Myriad, Neurocentia, Relmada, and Sage.

Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
University of Toronto, Canada
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Toronto, Canada
Board Chair, Depression and Bipolar Support Alliance
Board of Directors
Chicago, Illinois

Roger McIntyre, MD, FRCPC, has disclosed that he has received speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Eisai, Intra-Cellular, Abbvie. Dr. Roger McIntyre is CEO of Braxia Scientific Corp.